3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
About this article Cite this article Oft, H.C., Simon, D.W
Human clinical studies report measurable reductions in HbA1c levels, body-weightrelated endpoints, and improved insulin sensitivity markers compared to placebo-controlled groups
The translational value of targeting cuproptosis and copper metabolism lies in the identification of key regulatory molecules (e.g., FDX1, DLAT, ATP7A/B) and potential biomarkers (e.g., serum CP and NCC) that could guide clinical decision-making
Omega-3 fatty acids (2-4g daily) support cardiovascular health during metabolic changes and may enhance insulin sensitivity